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Background: Few studies have directly compared airway remodelling assessed by
computed tomography (CT) between asthma and chronic obstructive pulmonary disease
(COPD). The present study was conducted to determine whether there are any differences
between the two diseases with similar levels of airflow limitation under clinically stable
conditions.
Methods: Subjects included older male asthmatic patients (n Z 19) showing FEV1/FVC
<70% with smoking history less than 5-pack/year. Age- and sex-matched COPD patients
(n Z 28) who demonstrated similar airflow limitation as asthmatic patients and age-
matched healthy non-smokers (n Z 13) were recruited. Using proprietary software, eight
airways were selected in the right lung, and wall area percent (WA%) and airway luminal
area (Ai) were measured at the mid-portion of the 3rd to 6th generation of each airway.
For comparison, the average of eight measurements per generation was recorded.
Results: FEV1% predicted and FEV1/FVC was similar between asthma and COPD
(82.3  3.3% vs. 77.6  1.8% and 57.7  1.6% vs. 57.9  1.4%). At any generation, WA%
was larger and Ai was smaller in asthma, both followed by COPD and then controls. Signif-
icant differences were observed between asthma and controls in WA% of the 3rd to 5th
generation and Ai of any generation, while no differences were seen between COPD
and controls. There were significant differences in Ai of any generation between asthma
and COPD.; Ao, outer area of the bronchus; COPD, chronic obstructive pulmonary disease; CT, computed
, carbon monoxide diffusing capacity; FEV1, forced expiratory volume in 1 s; FRC, functional residual
CS, inhaled corticosteroid; IgE, immunoglobulin E; LAV, low attenuation volume; MMF, maximum mid-
me; SEM, standard error of measurement; TLC, total lung capacity; VA, alveolar volume; VC, vital
hree-dimensional.
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1276 K. Shimizu et al.Conclusions: Airway remodelling assessed by CT is more prominent in asthma compared
with age- and sex-matched COPD subjects in the 3rd- to 6th generation airways when
airflow limitations were similar under stable clinical conditions.
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Bronchial asthma is characterized by reversible airflow
limitation and airway hyper-responsiveness to constricting
stimuli. Some asthmatic patients have irreversible airflow
limitations despite treatment, possibly caused by airway
remodelling.1e3 In contrast, airflow limitation observed in
chronic obstructive pulmonary disease (COPD) is by defini-
tion not fully reversible. In both diseases, airway inflam-
mation is present, although the characteristics of the
inflammation are different. Airway remodelling is also
a common feature of both diseases, but the characteristics
differ in nature as well as in severity.
The inflammation and remodelling in these two diseases
have been described with regards to physiology,49 patho-
logy10e13 and biology.14e16 Differences in airway inflam-
mation have been well characterized between bronchial
asthma and COPD.4,13
However, few studies have directly compared airway
remodelling assessed by computed tomography (CT) in
asthma and COPD17,18 despite the increasing use of this
modality for the assessment of airway dimensions in these
diseases.19,20 Some investigators have speculated that airway
wall area is increased without a decrease in luminal area in
asthma,whereas increasedairwaywall area isassociatedwith
a decrease in luminal area in COPD.21,22 However, this spec-
ulation is based on results of two independent studies in
subjects with different levels of airflow limitation.
In the present study, possible differences in airway
dimensions between the two diseases were investigated
in clinically stable patients with similar levels of airflow
limitation. Specifically, we assessed proximal airway re-
modelling by CT and compared between subjects with
asthma and COPD. We hypothesized that airway remodel-
ling estimated by CT scans would be more prominent in
bronchial asthma, because the airways we could measure
were located in the proximal, but not in the distal, by
definition. Airflow limitation in bronchial asthma is char-
acterized by airway remodelling in the proximal airways
while that of COPD is characterized by mixture of emphy-
sema and airway remodelling in the small airways. Propri-
etary computer software enabling precise analysis of the
short-axis image of the airways perpendicular to the long-
axis at the 3rd- to 6th generation airways was used.23,24
Methods
Subjects
Subjects were recruited from the outpatient clinic of
Hokkaido University Hospital from October 2006 through
June 2009. First, asthmatic male patients who were older
than 55 years and had poorly reversible airflow limitation ofFEV1/FVC <70% despite appropriate drug therapy were
recruited. Diagnosis of bronchial asthma was made based
on the definition of American Thoracic Society, “Asthma is
a chronic inflammatory disorder of the airways. The
chronic inflammation causes an associated increase in
airway hyper-responsiveness that leads to recurrent
episodes of wheezing, breathlessness, chest tightness, and
coughing, particularly at night or in the early morning.
These episodes are usually associated with widespread but
variable airflow obstruction that in often reversible either
spontaneously or with treatment”.25 Additional entry
criteria included: i) clinically stable (no asthma attacks or
major changes in medication for more than 6 weeks before
study entry); ii) life-long non-smokers or smokers with
a lifetime smoking history less than 5-pack/year; and iii) no
apparent emphysema on CT by visual assessment. Male
patients with COPD were selected from subjects who
participated in the Hokkaido COPD cohort study.26 Subjects
were chosen based on age and values of FEV1/FVC, FEV1%
and all other data were blinded. Subjects in the COPD
group who had apparent giant bulla and/or bronchiectasis
which might have anatomically affected bronchial struc-
ture were excluded. Also recruited were age-matched male
healthy volunteers as controls with normal pulmonary
function who had no history of respiratory diseases or
respiratory symptoms.
All the subjects underwent CT and pulmonary function
tests sequentially on the same day. Asthmatic patients had
taken their regular medications on the examination day.
Patients with COPD had refrained from taking respiratory
medications for 1e2 days, according to the protocol of the
Hokkaido COPD cohort study.26
The study protocols were approved by the Clinical
Research Ethics Committee of Hokkaido University Hospital
on 6th July 2006. Written informed consent was obtained
from all the subjects.
CT data acquisition and analysis
CT was performed using a multidetector-row spiral CT
scanner with a 64 detector array (Aquilion Multi, TSX-101A/
6A; Toshiba Medical Systems, Gunma, Japan). Data were
acquired with the following parameters: 120 kVp, 300 mA,
64 detector  0.5-mm collimation, slice thickness 0.5 mm,
0.5 s/rotation, helical pitch 41. While subjects were in the
supine position, holding their breath at deep inspiration,
the entire lung was scanned. The data were transferred to
a workstation and then reconstructed into three-
dimensional (3D) images (AZE Ltd., Tokyo, Japan). The
detailed process of CT data acquisition and reconstruction
has been described previously.27
First, a three-dimensional bronchial skeleton was auto-
matically reconstructed using a certain threshold level,
determined on an individual basis (950HU to 980 HU) to
Airway remodelling assessed by CT in asthma and COP 1277obtain airway images as distal as possible. Any portions of
lung parenchyma remaining with the skeleton were manu-
ally removed to prevent analysis error. Finally, we obtained
a bronchial skeleton and were able to identify any bronchus
in the source images of axial, sagittal, and coronal slices.
The selected bronchial pathway was automatically con-
verted to a curved multiplanar reconstruction image. As the
automatically obtained bronchial skeleton often contained
only up to the 3rd- (segmental) to 5th generation airway,
depending on the quality of the images, airways were
selected and then extended to the 6th generation. Identi-
fication of the generation of bronchi was made by careful
inspection while simultaneously using the longitudinal and
short-axis images and searching for any bifurcation in the
entire circumference.
The bronchial long-axis image appeared as a straight
pathway, and short-axis images from the 3rd to the 6th
generation, were identified (Fig. 1). For measuring airway
dimensions, the software used the full-width at half-
maximum principle for defining the wall area. However,
as the automatically obtained outline of airway walls was
often out of contour, manual corrections were made as
follows. Based on manual plotting at several points, the
software used cubic spline interpolation and built a new
circle. Finally, values were obtained for the inner luminal
area (Ai) and the outer area of the bronchus (Ao) and wall
area (WA) was calculated as (Ao - Ai). Wall area percent
(WA%) was defined as (Ao - Ai)/Ao  100. A total of eight
airways per subject were chosen for the measurements,
one airway from each of the following bronchi: the apical
(B1), posterior (B2), and anterior (B3) of the upper lobe,
the lateral (B4) and medial (B5) of the middle lobe, and the
anterior basal (B8), lateral basal (B9), and posterior basal
(B10) of the lower lobe in the right lung. The measurement
site was generally at the midpoint between the bifurca-
tions. All these measurements were done by one of the
authors (K. S.) who was blinded to any of the subjects’
characteristics and pulmonary function data.
Total lung volume and volume-based severity of
emphysema were measured. In short, whole lung contain-
ing airways (A) were extracted from the 3D image of the
thorax, resulting in deletion of the heart and major vessels
in the lungs. Then the bronchial skeleton (B) was extracted
from the whole lung, resulting in the lung consisting of
parenchyma without either major vessels or proximal
bronchial trees. Total lung volume was defined as (A) e (B).
Severity of emphysema was assessed as low attenuation
volume (LAV), based on the threshold value of 950 HU.
LAV% was defined as lung low attenuation volume divided
by total lung volume.
All CT measurements were done by one author (KS) who
was blinded to the subjects’ information.Pulmonary function tests
Spirometry, carbon monoxide diffusion capacity, and lung
volume assessed by the helium closed-circuit method
(CHESTAC-33, CHEST M. I., Inc., Tokyo, Japan) were
measured. Spirometric measurements included forced vital
capacity (FVC), forced expiratory volume in 1 s (FEV1), and
maximal mid-expiratory flow (MMF). Lung volumemeasurements included total lung capacity (TLC), functional
residual capacity (FRC), and residual volume (RV). We used
the rolling seal type of spirometer, the CHESTAC-33 (CHEST
MI, Inc., Tokyo, Japan). The procedures and results of
pulmonary function tests met the requirements of the
pulmonary function test guidelines of the Japanese Respi-
ratory Society Guidelines,28 which are similar to those of the
American Thoracic Society. The diffusing capacity of the
lung for carbon monoxide (DLco), based on the single-breath
method, was also measured in all subjects according to the
pulmonary function test guidelines of the Japanese Respi-
ratory Society. DLco divided by alveolar volume (VA) was
expressed as percentage of predicted values according to
the prediction equations of Burrows.29 Lung volumes (total
lung capacity (TLC), functional residual capacity (FRC), and
residual volume (RV)) were measured by the helium closed-
circuit method. Lung volumes were expressed as
a percentage of predicted values according to the prediction
equations of Nishida.30 Spirometry was repeated 30 min
after inhalation of salbutamol (200 mg for bronchial asthma,
400 mg for COPD, as determined by the Hokkaido COPD
cohort study). Reversibility was defined as (post-bronchodi-
lator FEV1 e pre-bronchodilator FEV1)/pre-bronchodilator
FEV1  100. There were not significant differences between
the asthma and COPD groups in any indices of pre-
bronchodilator FEV1, post-bronchodilator FEV1, reversibility.
Statistical analysis
SPSS was used for all statistical analyses (SPSS, Tokyo,
Japan). All data are expressed as mean  standard error of
measurement (SEM) for comparison. For comparison of lung
volume, diffusing capacity, and %LAV between the asth-
matic patients and the COPD patients the t-test was used,
and analysis of variance was used for comparison of
parameters between the three groups (age, pulmonary
function tests, and airway dimensions). A p value <0.05 was
considered statistically significant.
Results
Characteristics in the three groups are summarized in
Table 1. Nineteen asthmatic patients and twenty-eight
patients with COPD and thirteen healthy controls fulfilled
the criteria. Classification of asthma was based on the
Global Initiative for Asthma 2005.31 One subject was clas-
sified as mild persistent, 11 subjects were classified as
moderate persistent and 7 subjects were classified as
severe persistent. All subjects except one were taking
inhaled corticosteroids. In asthmatic patients, 14 subjects
were life-long non-smokers and 5 subjects were ex-
smokers. Among the 28 COPD patients, 17 were classified
as mild and 11 were classified as moderate, according to
the GOLD stage.32 Airflow limitation indices such as FEV1%
predicted (82.3  3.3 vs. 77.6  1.8) and FEV1/FVC
(57.7  1.6 vs. 57.9  1.4) were similar between the two
disease groups. There were no significant differences either
in the spirometric data or the data of lung volumes. The
results of the reversibility test were similar in these two
groups, because the asthmatic patients had taken regular
medications and the COPD patients had refrained from
Table 1 Characteristics of the subjects.
Characteristic Control Bronchial asthma COPD
N 13 19 28
Age (y) 67.4  2.6 71.1  1.9 70.4  1.4
Height(cm) 163.0  0.2.2 162.0  1.2 164.4  1.3
Weight(kg) 62.9  3.2 62.9  1.7 63.7  2.1
Body Surface Area (m2) 1.7  0.1 1.7  0.0 1.7  0.0
Smokers
Non-smokers 13 14 0
Ex-smokers 0 5 24
Current smokers 0 0 4
Smoking history (pack-years) 0 3.6  0.8 65.4  5.9
Asthma duration (y) 20.0  4.0
Treatment
Inhaled corticosteroids (%) 94.7 0
Long-acting b2-agonist
Inhaler (%) 36.8 10.7
Transdermal patch (%) 21.1 3.6
Inhaled anticholinergics (%) 0 10.7
Theophylline (%) 15.8 21.4
Leukotriene receptor antagonists (%) 42.1 0
Oral steroids (%) 0 0
Blood eosinophils (/ml)(normal range:70e440) 304.7  52.3 227.9  30.1
Total IgE (IU/ml) 371.9  159.0 222.8  67.3
All the subjects were male.
Data are shown as mean  standard deviation.
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(Table 2). DLco% predicted and DLco/VA% predicted were
lower in the COPD group compared to the asthma group.
Similarly, the severity of emphysema assessed as %LAV was
significantly greater in COPD patients compared to asth-
matic patients and controls (Fig. 1).
The representative airway images from two typical cases
with similar airflow limitation are shown (Fig. 2) With
regard to airway dimensions, WA% was larger and Ai was
smaller at any generation of bronchi in the asthmatic
group, both followed by the COPD group and then the
controls (Figs. 3 and 4). Significant differences were
observed between the asthma and control groups in WA% of
the 3rd to 5th generation (p < 0.01) and Ai of any genera-
tion airway (p < 0.01 for 4th, p < 0.05 for 3rd, 5th, 6th),
while no differences were seen between the COPD and
control groups. There were significant differences in Ai of
any generation between asthma and COPD (p < 0.01 for
4th, 5th, p < 0.05 for 3rd, 6th). The means of calculated
calibers from Ai in the 3rd to the 6th generation airways
were 5.08 mm, 3.94, 3.15, 2.57 in COPD, and 4.56, 3.39,
2.67, 2.26 in bronchial asthma. There were no differences
in total lung volume determined by CT among the asthma,
COPD, and control groups (4239.9  204.5, 4252.6  199.3,
and 4223.8  251.7 cm3, respectively).Discussion
In the present study, changes in airway dimensions at the
3rd to 6th generation airways assessed by 3D-CT were moreprominent in older asthmatic patients compared with age-
matched male COPD patients with clinically stable disease
and similar levels of airflow limitation. At any generation,
WA% was larger and Ai was smaller in the asthma group,
followed by the COPD group and then the controls. Signif-
icant differences were observed only between the asthma
and control groups in WA% of the 3rd to 5th generation
airways and Ai of any generation airway, but not in any
variable between the COPD and control groups. There were
significant differences in Ai of any generation airway
between the asthma and COPD groups.
Despite similar levels of FEV1/FVC, FEV1%, and lung
volumes (including RV/TLC), there was a marked difference
in DLco/VA between the asthma and COPD groups. In
addition, %LAV assessed by CT showed a marked difference
between the asthma and COPD groups. These data suggest
that the presence of emphysema was significant and
contributed to airflow limitation in COPD. Moreover,
considering previous reports13 on the airway pathology of
asthma and COPD, it is likely that, under similar airflow
limitations, airway inflammation and/or remodeling are
more prominent in the proximal airways in asthma
compared with in COPD. In COPD, the small airways and
emphysema are likely to be significant contributing factors
to airflow limitation. Thus, the present study clearly
demonstrated that when airflow limitation is mild to
moderate, 3D-CT has the capability to demonstrate
differences in airway dimensions between asthma and
COPD patients.
In the present study, subjects were selected so that
patients with asthma and COPD were matched for airflow
Table 2 The results of pulmonary function tests.
Control Bronchial asthma COPD
N 13 19 28
Pulmonary function tests
VC, l 3.8  0.2 3.8  0.1 3.8  0.1
VC (%predicted) 113.5  3.5 111.1  3.2 108.0  2.0
FEV1, l 2.9  0.1 2.1  0.1b 2.2  0.1b
Post-bronchodilator FEV1, l 2.2  0.1 2.3  0.1
Reversibilitya(%) 6.9  1.8 5.2  0.9
FEV1(%predicted) 102.2  2.5 82.3  3.3b 77.6  1.8b
FEV1/FVC (%predicted) 78.0  1.4 57.7  1.6b 57.9  1.4b
MMF (%predicted) 44.3  4.0 44.5  2.7
DLCO (%predicted) 124.7  5.0 86.7  4.6c
TLC (%predicted) 105.6  2.7 106.5  2.3
FRC (%predicted) 98.9  3.7 103.7  3.2
RV (%predicted) 104.1  4.4 104.5  3.6
RV/TLC (%) 36.6  1.3 40.0  2.6
VC, vital capacity; FEV1, forced expiratory volume in 1 s; MMF, maximum mid-expiratory flow rate; DLCO, carbon monoxide diffusing
capacity; VA, alveolar volume; TLC, total lung capacity; FRC, functional residual capacity; RV, residual volume. Data are shown as
mean  standard deviation.
a Reversibility(%) is defined as (post-bronchodilator FEV1 e pre-bronchodilator FEV1)/pre-bronchodilator FEV1  100.All the subjects
were male. Asthmatic patients had taken their regular medications prior to the reversibility test on the examination day. Patients with
COPD had refrained from taking respiratory medications for 1e2 days, according to the protocol of the Hokkaido COPD cohort study.
b p<0.05: Significantly different from controls.
c p<0.05: Significantly different from bronchial asthma.
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two previous studies have attempted to compare airway
dimensions between asthma and COPD using CT data. In
one study,17 subjects were not matched for age or sex,
which could have caused significant biases.3235 Further-
more, the asthma group included a substantial number of
smokers. In the other study,18 all parameters of airway
dimensions in HRCT analysis, including airway wall area,
airway wall area%, inner luminal area, airway luminal
diameter and wall thickness, were reported to be similar in
the subjects with the two diseases and similar airflow
limitations. However, only the airways in which the ratio ofBA COPD
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A
[%]
Figure 1 Comparison of variables reflecting severity of emphysem
predicted were lower in the COPD group compared to the asthma
significantly greater in COPD patients compared to asthmatic patien
carbon monoxide, VA: alveolar volume at the measurement of DLco R
lung CT data. See text for the assessment of %LAV. yp < 0.05, yyp < 0the diameter of the long-axis to that of the short-axis was
less than 1.2 were measured, thus allowing inclusion of
some airways cut obliquely on the CT slice. Additionally,
random selection of airways might have led to comparison
of airways of different generations and different sizes.
Another explanation might be that the degree of airflow
limitations in bronchial asthma was milder compared with
that of COPD although not statistically significant, in other
words, the two groups were not so exactly matched for
airflow limitation indices as in our study, which might have
obscured the difference. In the present study, lung volume
when the CT was taken was considered as a possible0
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LAV%
BA COPD
[%]
a between subjects with bronchial asthma and COPD. DLco/VA%
group and the severity of emphysema assessed as %LAV was
ts. Left panel: DLco/VA, %predicted; DLco: diffusion capacity of
ight panel: % lung attenuation volume (%LAV) assessed by whole
.01.
Figure 2 The representative airway images from two typical cases with similar airflow limitation. a. Images of a patient with
bronchial asthma (FEV1, %predicted 63.2%, FEV1/FVC 52.4%). b Images of a patient with COPD (FEV1,%predicted 62.9%, FEV1/FVC
49.8%) Short-axis image of the bronchus in i) the third generation ii) the forth generation iii) the fifth generation iv) the sixth
generation are shown. v) is the curved multiplanar reconstruction image image and gray lines and circles indicate the same sites
analyzed. Short-axis images, obtained from a curved multiplanar reconstruction image, are precisely perpendicular to the long-axis
of the airway. Identification of the generation of bronchi relied on careful inspection, simultaneously using longitudinal and short-
axis images and searching for any bifurcations in the entire circumference. At each bifurcation, we randomly selected one
bronchus. Images of i), ii), iii), iv) in a, b are expressed by the same magnification.
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measuring airway dimensions. Lung volume assessed by CT
volumetric data demonstrated no significant differences
between asthma and COPD, which again strengthened the
results of the present study.
We have previously reported the relationships of
airway dimensions, WA% and Ai, with airflow limitation
indices such as FEV1, % predicted in older patients with
clinically stable asthma36 and also patients with COPD,23
in both of which the subjects displayed variable levels
of airflow limitation. We found significant correlations of
airflow limitation indices with airway dimensions in the
3rd to 6th generations with similar correlation coefficients
in patients with bronchial asthma, and on the other hand,
in patients with COPD, the correlation coefficients that
we found similarly significant improved better as the
airways became smaller in size from the 3rd to 6th
generations. These study prompted us to examine the two
diseases with similar levels of airflow limitation under
stable conditions and we hypothesized that airwayremodelling estimated by CT scans would be more prom-
inent in bronchial asthma.
Structural and/or pathological differences that may
exist between subjects with the two diseases cannot be
judged from the present study. However, considering
previously reported pathology,13 it can be speculated that
in asthma with poorly reversible airflow limitation there is
remodelling consisting of increased airway smooth muscle
mass.37 On the other hand, in COPD with a mild to
moderate degree of airflow limitation, airway inflammation
and/or remodelling occurs mainly at the small airways
rather than the proximal airways. This is particularly the
case when few chronic bronchitis symptoms exist. Loss of
lung elastic recoil as a result of established emphysema is
another characteristic of COPD contributing to collapsing
airways37 and thus to airflow limitation.
Previous studies using CT assessment have suggested
that, compared to healthy subjects, airways of patients
with asthma were not narrowed despite the presence of
airflow limitation and airway wall thickening.21,38 This
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Figure 3 Comparison of WA% among healthy controls, subjects with bronchial asthma, and subjects with COPD. WA% was larger
at any generation of bronchi in the asthmatic group, both followed by the COPD group and then the controls Data expressed as the
average per generation of eight bronchi in the right lung at the 3rd- to 6th generation airways. WA%: airway wall area divided by
total airway area expressed as a percentage. yp < 0.05, yyp < 0.01.
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Figure 4 Comparison of Ai among healthy controls, subjects with bronchial asthma, and subjects with COPD. Ai was smaller at
any generation of bronchi in the asthmatic group, both followed by the COPD group and then the controls Data expressed as the
average per generation of eight bronchi in the right lung at the 3rd- to 6th generation airways. Ai: inner luminal area of the airway;
BSA: body mass index. yp < 0.05, yyp < 0.01.
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of 3rd generation airways. In the present study, airway
narrowing was particularly detected in 4th and 5th gener-
ation airways in asthma patients.
There were some limitations in the present study. 3D
airway analysis has technological limitations; it adopts the
full-width at half-maximum principle for determination of
the airway wall, an algorithm that has been reported to
underestimate airway luminal area and to overestimate
airway wall thickness, particularly in small-diameter
airways.39 However, comparison of data from the same
generation (i.e., similar-sized airways) between subjects
might have minimized systemic errors. The same trend was
observed among the 3rd to 6th generation bronchi, sup-
porting the findings of this study. Second, only elderly male
patients were selected for this study, and thus the results
may not be extrapolated to female patients and/or young
patients with asthma. In COPD, there have been some
reports which have focused on gender differences in the
contribution of airway disease and emphysema to airflow
limitation.33,35 Third, patients were recruited only with
mild to moderate degrees of airflow limitation. This is
because few patients with clinically stable asthma showed
severe airflow limitation under appropriate therapy. If we
could recruit the old patients with severer asthma, they
might share similarities with COPD particularly at the
smaller airways. Finally, residual reversibility of airflow
limitation was found both in the asthmatic and COPD groups
when CT was performed. However, the magnitude of
residual reversibility was small in both groups, and there-
fore probably did not significantly bias the main findings.
In conclusion, in older male patients with clinically stable
disease and mild to moderate airflow limitation, airway
remodeling at the 3rd to 6th generation bronchi assessed by
3D-CTwas more prominent in patients with bronchial asthma
compared with age-matched COPD patients.Acknowledgements
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